{'fraction_non_alphanumeric': 0.032904148783977114, 'fraction_numerical': 0.011444921316165951, 'mean_word_length': 5.363636363636363, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
218C: PHARMACOLOGICAL THERAPY FOR SALVAGE OF EX-VIVO ISCHEMIC HUMAN SKELETAL MUSCLE FROM ISCHEMIA/REPERFUSION (I/R) INJURY

Introduction: Prolonged ischemia can occur in amputated limbs due to delay in transporting patient, and there is no opportunity for prophylactic treatment against muscle I/R injury when blood flow is re-established. There is evidence that reperfusion injury in animal heart is caused by opening of mitochondrial permeability transition pores (mPTP), resulting in mitochondrial Ca2+(mCa2+) overload and dysfunction and cell death. Our aim was to study the efficacy of mPTP inhibitors cyclosporin A (CsA) and NIM811 in salvage of ischemic human skeletal muscle from I/R injury.